Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of enzalutamide vs
bicalutamide in asymptomatic or mildly symptomatic patients with prostate cancer who have
disease progression despite primary androgen deprivation therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Medivation, Inc. Pfizer
Collaborators:
Astellas Pharma Inc Medivation LLC, a wholly owned subsidiary of Pfizer Inc.